Treats osteoarthritis of the knee(s). ANDA 203818, held by Sun Pharma Canada. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 203818 (Diclofenac Sodium), held by Sun Pharma Canada, was first approved by FDA on Nov 26, 2014, with 3 approved supplements and 0 published complete response letters.
Diclofenac sodium topical solution, USP is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 26, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1.5% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 30, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 2, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 26, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters